Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C

Y. Karino, I. Ozeki, S. Hige, M. Kimura, T. Arakawa, T. Nakajima, Y. Kuwata, T. Sato, T. Ohmura and J. Toyota
Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan

Received May 2013; accepted for publication July 2013

SUMMARY. We aimed to examine the relationship between renal dysfunction and anaemia that may develop during combination therapy involving pegylated interferon, ribavirin and telaprevir (PEG-IFN/RBV/TVR) for the treatment of chronic hepatitis C. Sixty-eight patients with genotype 1b high viral loads were treated with PEG-IFN/RBV/TVR. Peg-IFN and RBV doses were administered according to body weight. TVR was prescribed at 2250 mg/day for 44 patients and at 1500 mg/day for 24 patients who had low haemoglobin level (<12 g/dL). When anaemia had developed, the RBV dose was decreased. The serum TVR concentration at day 8 was measured, and the serum RBV concentration was measured serially. The estimated glomerular filtration rate (eGFR) was estimated to assess renal function. At week 1, serum TVR concentration was not correlated with a decrease in eGFR; however, the TVR dose, on a weight basis (mg/kg), and eGFR were correlated ($r = 0.2691$; $P = 0.0265$). Moreover, there was a negative correlation between eGFR and RBV serum concentration ($r = -0.3694$; $P = 0.0025$), and the serum RBV concentration and decrease in the haemoglobin were significantly correlated from week 1 to week 8. In triple therapy, the TVR dose per weight is correlated with a decline in renal function. Thus, the serum concentration of RBV increases, with a concomitant decrease in haemoglobin. It is important to adjust the doses of TVR and RBV to avoid excessive serum RBV levels and the development of severe anaemia, to achieve a good clinical effect.

Keywords: anaemia, estimated glomerular filtration rate, hepatitis C virus, ribavirin, telaprevir.

INTRODUCTION

An estimated 170 million people are chronically infected with hepatitis C virus (HCV) worldwide [1]. Approximately 30% of the patients with chronic HCV develop life-threatening liver disease, such as decompensated cirrhosis and hepatocellular carcinoma [2,3]. Since Hoofnagle et al. [4] first reported the effectiveness of interferon (IFN) in the treatment of the so-called non-A non-B chronic hepatitis, IFN has played a central role in the antiviral therapy for chronic hepatitis C. Until recently, combined therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV), for 48 weeks, has been the standard-of-care for patients infected with HCV genotype 1 (HCV-1), which is the most prevalent genotype worldwide. However, sustained virological response (SVR) is achieved in only 42–52% of the patients treated with this regimen [5–7].

To achieve a better antiviral effect, investigators have developed several direct-acting antivirals, represented by NS3/4A protease inhibitors and NS5B polymerase or NS5A inhibitors [8]. Of these, telaprevir (TVR), an inhibitor of the NS3/4A serine protease, in combination with PEG-IFN and RBV (triple therapy), has been most promising and has been reported to achieve an SVR of up to 70% [9–13]. However, adverse events develop more frequently in patients treated with protease inhibitors than in those treated only with PEG-IFN and RBV. In TVR trials, rash, anaemia, pruritus, nausea and diarrhoea were found to develop more frequently in individuals who received PEG-IFN and RBV along with TVR than in those individuals who received PEG-IFN and RBV only [11]. In addition, a renal functional disorder associated with TVR therapy became evident in Japan after the Ministry of Health, Labour and Welfare approved the use of TVR [14]. RBV is excreted in the urine, and diminished renal function can interfere with its metabolism [15]. In this
study, we aimed to examine the relationship between renal dysfunction and anaemia in patients undergoing triple therapy for HCV.

PATIENTS AND METHODS

Patients

We enrolled 68 patients with HCV-1 who were treated with PEG-IFN/RBV/TVR at the Sapporo Kosei General Hospital. All participants provided written informed consent according to the process approved by the hospital’s ethical committee, and the study conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Patients were excluded if they had evidence of autoimmune hepatitis; alcoholic liver disease; congestive liver failure; hepatitis B virus infection; markers for human immunodeficiency virus; hepatocellular carcinoma or other malignancies; or hepatic decompensation, associated with jaundice, ascites, encephalopathy, or gastrointestinal bleeding. The patient characteristics are shown in Table 1.

All patients were treated with PEG-IFN-a-2b, RBV and TVR triple therapy. PEG-IFN-a-2b (MSD, Tokyo, Japan) was injected subcutaneously at a median dose of 1.5 g/kg per week. TVR and RBV doses were adjusted according to guidelines for the treatment of hepatitis B and C, established in 2012 by the Japanese Ministry of Health, Labour and Welfare [16]. Usually, 750 mg of TVR (Mitsubishi Tanabe Pharma, Tokyo, Japan) was administered orally every 8 h after meals. The dose of RBV (MSD) was adjusted according to the individual’s body weight (600 mg for individuals weighing ≤60 kg; 800 mg for individuals weighing <60 to ≤80 kg; and 1000 mg for individuals weighing >80 kg) and was orally administered after breakfast and dinner. If the initial haemoglobin (Hb) level was <14 mg/dL in women, or <13 mg/dL in men, the RBV dose was reduced by 200 mg. Triple therapy with TVR was administered for 12 weeks, followed by an additional 12 weeks of PEG-IFN-a-2b and ribavirin therapy (combination therapy). If severe anaemia was present, the dosage of RBV, followed by that of TVR, was adjusted, as determined by the chief physician.

Hepatitis C virus genotype

Hepatitis C virus genotype was determined by analysis of the sequence in the NS5B region.

Hepatitis C virus RNA levels

Hepatitis C virus RNA levels were determined using the COBAS TaqMan HCV test (Roche Diagnostics, Tokyo, Japan). The linear dynamic range of the assay was 1.2–7.8 log10 IU/mL.

Table 1 Characteristics of study patients in each telaprevir (TVR) dose

| Total | 1500 mg/day | 2250 mg/day | P |
|-------|-------------|-------------|---|
| Number | 68 | 24 | 44 | <0.0001 |
| Sex (M/F) | 34/34 | 4/20 | 30/14 | |
| Age (years old) | 55.8 ± 10.5 | 59.6 ± 9.4 | 53.7 ± 10.6 | 0.0023 |
| Height (cm) | 161.4 ± 7.8 | 157.1 ± 6.8 | 163.8 ± 7.4 | 0.0023 |
| Weight (kg) | 62.1 ± 10.2 | 57.9 ± 9.0 | 64.5 ± 10.2 | 0.0090 |
| rs12979860 (CC/TC/TT) | 43/23/2 | 16/8/0 | 27/15/2 | 0.5186 |
| rs1127354 (CC/CA/AA) | 51/16/1 | 18/5/1 | 33/11/0 | 0.7695 |
| WBC (×10^9/mm³) | 4663 ± 1271 | 4107 ± 1101 | 4934 ± 1288 | 0.0074 |
| Haemoglobin (g/dL) | 13.6 ± 1.2 | 12.9 ± 1.0 | 14.0 ± 1.1 | 0.0005 |
| Platelet (×10^9/mm³) | 16.6 ± 4.6 | 15.8 ± 4.1 | 17.1 ± 4.8 | 0.3521 |
| ALT (IU/L) | 57.1 ± 47.4 | 51.3 ± 39.8 | 60.3 ± 51.3 | 0.2905 |
| GGTP (IU/L) | 52.1 ± 53.7 | 44.7 ± 44.9 | 56.1 ± 58.0 | 0.1902 |
| estimated glomerular filtration rate (mL/min/1.73 m²) | 85.6 ± 15.2 | 81.5 ± 11.7 | 88.1 ± 16.4 | 0.1902 |
| Viral genotype (1b/others) | 68/0 | 24/0 | 44/0 | |
| Virus titre (log IU/mL) | 6.5 ± 0.6 | 6.2 ± 0.7 | 6.5 ± 0.7 | 0.2456 |
| Pegylated interferon (µg/kg) | 1.52 ± 0.11 | 1.54 ± 0.13 | 1.52 ± 0.10 | 0.5004 |
| TVR (mg/kg) | 32.5 ± 6.8 | 26.5 ± 3.9 | 35.8 ± 5.7 | <0.0001 |
| Ribavirin (RBV) (mg/day) | 19/19/27/3 | 14/9/1/0 | 5/10/26/3 | <0.0001 |
| (400/600/800/1000) | | | | |
| RBV (mg/kg) | 10.2 ± 2.0 | 8.5 ± 1.2 | 11.2 ± 1.7 | <0.0001 |

Data are presented as mean ± SD.

© 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd
**Single-nucleotide polymorphism genotyping**

We genotyped each patient for two single-nucleotide polymorphism (SNPs): rs12979860, an IL28B (interleukin 28B) SNP previously reported to be associated with therapeutic outcome [17], and rs1127354, an inosine triphosphatase (ITPA) SNP reported to be associated with ribavirin-induced anaemia [18]. Samples were genotyped using the Illumina HumanHap610-Quad Genotyping BeadChip (Illumina, San Diego, CA, USA) or the Invader or TaqMan assay, as described previously [19,20].

**Drug concentrations**

Blood samples were collected immediately prior to the administration of TVR or RBV in the morning on days 8, 15 and 29. Serum concentrations of TVR were determined at day 8 (week 1) using a high-performance liquid chromatographic (HPLC) apparatus fitted with a mass spectrometer (LC-MS/MS) (Mitsubishi Chemical Medience Corporation, Tokyo, Japan), and the serum concentration of RBV was measured at day 8 (week 1), day 15 (week 2) and day 29 (week 4) by HPLC (SRL, Inc. Tokyo, Japan) using serum stored at −80 °C.

**Renal function**

To assess the renal function, we used the estimated glomerular filtration rate (eGFR), which was calculated according to the equation [194 × (Scr⁻¹.094) × (age⁻¹.287) × (0.739 for women) (mL/min/1.73 m²) serum creatinine (Scr)], as established by the Japanese Society of Nephrology in 2008 [21].

**Statistical analysis**

Continuous variables between groups were compared using the Mann–Whitney U-test, and categorical variables were compared using the Fisher’s exact test. The correlation between the two groups was calculated using Spearman’s rank correlation coefficient. Statistical analyses were performed using the statistical software SAS version 9.1 (SAS Institute Inc., Cary, NC, USA); a P value of <0.05 was considered significant.

**RESULTS**

**Telaprevir dose and patient background**

The TVR dose was administered according to initial Hb level and gender. The dose per weight of TVR and RBV was significantly higher in the patients receiving the 2250-mg TVR dose; however, the dose per weight of PEG did not differ according to the TVR dose. With regard to background factors, an increased age, higher proportion of women, decreased height and weight, lower white blood cell count and lower levels of Hb and eGFR were noted in the 1500-mg TVR dose group (Table 1).

**Telaprevir serum concentration**

The TVR serum concentration (trough value) at day 8 (week 1) of triple therapy was measured in 65 of 68 cases. The TVR concentration varied widely (1076–4598 ng/mL). The mean TVR serum concentration of patients receiving the 2250-mg TVR dose was higher than that of patients receiving the 1500-mg TVR dose (2739 ± 833 ng/mL vs 2361 ± 838 ng/mL, respectively); however, the difference was not statistically significant (P = 0.075). The patients’ background factors were used as independent variables in the multiple regression analysis (Table 1), and the TVR serum concentration was estimated using the following formula: TVR concentration (ng/mL) = 56.2 × TVR (mg/kg) – 37.6 × height (cm) + 6878.4 (R² = 0.3500, P < 0.001) (Fig. 1). In addition, the dose per weight of TVR (mg/kg) and the TVR serum concentration were significantly correlated (r = 0.4795, P < 0.001) (Fig. 2).

**Correlation of telaprevir serum concentration, dose per weight of telaprevir (mg/kg) and decline in renal function**

The patients’ eGFR declined at an initial stage during triple therapy, and the decline continued for the duration of TVR treatment [baseline: 85.8, week 1: 69.6, week 2: 70.2, week 4: 69.2, week 8: 66.6, week 12: 72.5 (mL/min/1.73 m²)] (Figure S1). The total TVR serum concentration (trough value) at week 1 of the triple therapy was not correlated with the delta eGFR; however, the dose per body weight of TVR (mg/kg) was significantly correlated with delta eGFR at week 1 and week 4, but not at week 8 (Fig. 3).

**Correlation of renal function and ribavirin serum concentration**

There was no correlation between the dose per weight of RBV (mg/kg) and eGFR or delta eGFR at week 1 (P = 0.6422 and P = 0.1152, respectively). However, at week 1, there was a significant negative correlation between eGFR and RBV serum concentration, and a significant positive correlation between delta eGFR and RBV serum concentration (r = −0.3694, P = 0.0025; r = 0.3189, P = 0.0096, respectively) (Fig. 4). By multiple regression analysis, the serum concentration of RBV at week 1 was estimated using the formula: RBV concentration (ng/mL) = 413.5 × sex (male = 1, female = 2) + 12.8 × age (years) + 163.5 × RBV (mg/kg) – 5.9 × eGFR (1 week) – 1291.6 (R² = 0.4631, P < 0.001) (Fig. 1). Thus, in addition to age, sex and the dose per weight of
RBV (mg/kg), eGFR was also correlated with the RBV serum concentration.

Correlation of telaprevir, ribavirin serum concentration and haemoglobin level

The TVR serum concentration at week 1 was significantly negatively correlated with Hb levels at week 3, 6, 7 and 8 of treatment and was significantly positively correlated with the delta Hb level only at week 3 of treatment. The RBV serum concentration at week 1 showed a significant negative correlation with the Hb levels from week 2 to week 8 and a significant positive correlation with the delta Hb levels from week 1 to week 8. Moreover, the RBV serum concentration at week 2 and week 4 showed a significant negative and positive correlation with the Hb levels and the delta Hb levels, respectively (Table S1).

DISCUSSION

As RBV is usually eliminated by renal filtration, the development of renal failure would result in the accumulation of RBV, particularly in red blood cells, and may induce haemolytic anaemia. Triple therapy that includes TVR has two well-known serious side effects: anaemia and dermatopathy. In addition to these side effects, a decline in renal function, which was noted in Japan after TVR was made commercially available, is now recognized as a significant problem; this decline in renal function was not noted with PEG-IFN and RBV combination therapy. Renal dysfunction has also recently been associated with boceprevir use [22, 23]. The mechanism responsible for the decline in renal function caused by TVR remains unknown; however, the risk factors in Japanese patients include receiving a 2250-mg TVR dose, advanced age and low Hb levels at the start of the therapy.

The serum concentration of TVR reportedly reaches a steady state in 2–7 days of treatment [24, 25]. In the present study, the trough serum concentration of TVR at day 8 of triple therapy was estimated through multiple regression analysis using the formula: TVR (ng/mL) = 56.2 × TVR (mg/kg)−37.6 × height (cm) + 6878.4. The dose per weight of TVR (mg/kg) was the strongest determinant of the TVR serum concentration. The renal function impairment in patients treated with the TVR/PEG-IFN/RBV combination therapy was noted at an early stage in the treatment and persisted throughout the TVR treatment duration, but gradually improved after TVR treatment was
discontinued. In patients receiving the TVR/PEG-IFN/RBV combination therapy, although the serum TVR concentration at week 1 was not significantly correlated with the decline in renal function during week 1, the dose per weight of TVR (mg/kg) showed a significant correlation with the decline in renal function during week 1. Thus, the degree of renal function impairment worsened with an increase in the dose per weight of TVR (mg/kg). Furthermore, because RBV is eliminated by renal filtration [15], it is expected that a decline in renal function will result in an increase in serum RBV concentration. In the present study, the serum concentration of RBV at week 1 is positively correlated with delta eGFR.

In patients receiving TVR-containing triple therapy, the development of anaemia can lead to dose reduction or discontinuation of the drug. The administration of TVR or RBV alone can cause anaemia. However, the renal dysfunction caused by TVR can exacerbate this problem by increasing the serum concentration of RBV and thus increase the severity of haemolytic anaemia.

Because TVR was administered at a fixed dose of 2250 mg/day during the third phase of the clinical trial for TVR/PEG-IFN/RBV combination therapy in Japan, the dose per weight of TVR varied widely (25.7–55.3 mg/kg) [13]. Moreover, by multivariate analysis, we noted that the factor that contributed significantly to a decline in the Hb level to less than 8.5 g/dL – which necessitated the discontinuation of TVR/PEG-IFN/RBV combination therapy – was a relatively high dose per weight of TVR [26]. In the present study, sex, age and dose per weight of RBV, the eGFR at week 1 was a regulating factor for RBV serum concentration. After examining the relationships among TVR serum concentration, RBV serum concentration, and Hb level, the TVR serum concentration at week 1 was negatively correlated with the Hb level at week 3, 6, 7 and 8 and was positively correlated with the delta Hb level at week 3. The RBV serum concentration was negatively correlated with the Hb level from week 2 to 8 and positively correlated with the delta Hb level from week 1 to 8. Similarly, the serum RBV concentration at weeks 2 and 4 was correlated with the Hb level and the delta Hb level, respectively.

Fig. 3 Correlation between TVR (mg/kg) and delta eGFR. The dose per weight of TVR (mg/kg) is significantly correlated with the delta eGFR, indicating a decline in renal function from the baseline, at week 1 and week 4, but not at week 8 of triple therapy.

Fig. 4 Correlation between RBV concentration (Week 1) and eGFR (Week 1) and delta eGFR (Week 1). The eGFR at week 1 is negatively correlated with eGFR, whereas the serum RBV concentration at week 1 is positively correlated with delta eGFR.
Fig. 5 Cascade reaction of RBV induced anaemia during triple therapy. In the triple therapy, as the TVR concentration increases, renal function (and consequent excretion of RBV) decreases; the RBV serum concentration increases, and the Hb level decreases. In addition, TVR has a mild direct hemolytic effect (interrupted arrow on the right), contributing to the decrease in Hb concentrations. The declining Hb levels may require discontinuation of the regimen or reduction in the anti-HCV drug doses and, consequently, may result in a reduced antiviral effect. For patients requiring TVR/PEG-IFN/RBV combination therapy, the interactions of TVR and RBV should be considered while determining the optimal doses of TVR and RBV.

ACKNOWLEDGEMENTS AND DISCLOSURE

Karino T., Ozeki I., Hige S., Kimura M., Arakawa T., Nakajima T., Kawanata Y., Sato T., Ohmura T. and Toyota J. who have taken part in this study declared that we do not have anything to disclose regarding funding or conflict of interest with respect to manuscript. We thank T. Harada for his advice regarding data analysis in the present study. In addition, we thank Dr K. Chayama for his assistance in identifying IL28B and ITPA genotypes.

REFERENCES

1 World Health Organization. Hepatitis C (Global Alert and Response, 2002). Geneva, Switzerland: World Health Organization. 2002. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html (accessed 12 February 2012).
2 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21–S29.
3 Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S54–S66.
4 Hoofnagle JH, Mullen KD, Rustgi V et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575–1578.
5 Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
6 Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
7 Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
8 Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 2011; 31: S68–S77.
9 Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839–1850.
10 McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827–1838.
11 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–2416.
12 Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014–1024.
13 Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N, Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78–84.
14 Ozeki I, Kimura M, Arakawa T et al. Renal dysfunction with telaprevir in combination with peginterferon alfa-2b and ribavirin therapy. Kanzo 2012; 53: 425–428.
15 Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43: 140–146.
16 Study group of the Japanese Ministry of Health, Labour and Welfare for the standardization of the latest therapy in the viral hepatitis. Guidelines on 2012 for the treatment of hepatitis B and C. Available at: https://www.jsh.or.jp/doc/guidelines/H24_guideline.pdf (accessed 10 April 2011).

17 Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.

18 Fellay J, Thompson A, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405–408.

19 Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A High-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471–477.

20 Suzuki A, Yamada R, Chang X et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395–402.

21 Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53(6): 982–992.

22 Kapelusznil L, Majid AM, Cox ER et al. Boceprevir is associated with decline in renal function in a cohort of HCV-treated patients. J Hepatol 2013; 58: s342.

23 Mauss S, Eisenbach C, Moog G et al. Substantial renal impairment is not infrequent in HCV patients under triple therapy with telaprevir or boceprevir. J Hepatol 2013; 58: s358.

24 Yamada I, Suzuki F, Kamiya N et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 1.2 weeks in hepatitis C virus genotype 1b infection. J Viral Hepatitis 2012; 19: e112–e119.

25 Suzuki F, Suzuki Y, Sezaki H et al. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2012; 43(7): 691–701.

26 Karino Y, Ozeki I, Hige S et al. Analysis of optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy. J Hepatol 2013; 58: s338.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Table S1. Correlation between serum concentration of RBV or TVR and Hb, as well as delta Hb levels. The reduction in the eGFR is evident as early as week 1 of therapy and persists for the duration of treatment.

Figure S1. The reduction in the eGFR is evident as early as week 1 of therapy and persists for the duration of treatment.